There is a scenario in which the United Kingdom data supports NACI's giving guidance that the messenger RNA vaccines are a suitable second dose, and in that instance, you might see, yes, less demand for AstraZeneca.
I think there will continue to be a demand for AstraZeneca by people who are looking for a second dose and want the same vaccine, and so on, and as I think Theresa mentioned earlier, the messenger RNA vaccines don't always....
You can have an allergic reaction, and so on, so you want to have a diversity of portfolio. Therefore, there will be some demand, but much less if it happened that way.